InflaRx appoints Alperovich. Needham targets InflaRx stock at USD 8.00

Published on 10/20/2026 at 13:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

InflaRx named Alperovich on October 1, 2026, after 20 years in drug development. InflaRx stock costs EUR 1.34 on October 20, 2026, with Needham at USD 8.00.

Pipeline and trading markers

InflaRx appointed Gabriela Alperovich on October 1, 2026.
Izicopan achieved at least 90.00 percent C5a blockade over 14 days.
InflaRx stock trades at EUR 1.34 at 1:06 p.m. CEST at Lang & Schwarz on October 20, 2026.

IFRX, NL0012661870, Illustration mit AI erstellt.

InflaRx (NL0012661870) appointed Gabriela Alperovich as senior vice president and global head of clinical development on October 1, 2026, after more than 20 years in the pharmaceutical industry, according to InflaRx. Needham has a USD 8.00 price target for InflaRx stock after initiating coverage on September 14, 2026, as reported by MarketBeat.

A clinical hire with renal expertise

Alperovich joined from CSL Vifor, where she had served as executive director and global clinical lead for cardiovascular and renal programs. Her background covers Phase 2 and registrational programs in immune-inflammatory kidney diseases, giving the appointment a direct connection to InflaRx's izicopan development strategy.

Three milestones shaped the pipeline

On May 8, 2026, InflaRx announced the closing of a USD 150.00 million underwritten offering on its investor-relations page. On August 6, 2026, the company reported a quarterly loss of USD 0.11 per share against a USD 0.07 consensus estimate, according to MarketBeat. On October 1, 2026, InflaRx appointed Alperovich to lead clinical development.

What does the kidney program mean?

InflaRx's October 2, 2026 release said izicopan achieved at least 90.00 percent blockade of C5a-induced neutrophil activation over a 14-day dosing period. The company plans development in ANCA-associated vasculitis and additional renal diseases, while also pointing to Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria, according to InflaRx.

The next two dates are clinical

The late-breaking kidney poster is scheduled for October 22, 2026, during the American Society of Nephrology's Kidney Week. MarketWatch lists November 6, 2026, as the expected date for InflaRx's third-quarter 2026 earnings, while its estimates page shows a consensus adjusted earnings-per-share estimate of USD -0.06 for that quarter, according to MarketWatch.

Euro quote and Nasdaq context

InflaRx stock had a USD 0.80 to USD 2.95 52-week range and a USD 234.3 million market capitalization in the October 13, 2026 market context reported by MarketBeat. At Lang & Schwarz, InflaRx was trading at EUR 1.34 on October 20, 2026, at 1:06 p.m. CEST.

InflaRx was trading at EUR 1.34 at Lang & Schwarz on October 20, 2026 at 1:06 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of InflaRx stock.